Entrada Therapeutics director Kush Parmar sells $807,027 in shares By Investing.com

Kush Parmar, a Director and 10% Owner of Entrada Therapeutics, Inc. (), recently sold shares of the company’s common stock totaling $807,027. The transactions occurred over two days, involving a total of 116,474 shares, with prices ranging between $6.85 and $6.93 per share.

On July 30, 2026, Parmar disposed of 114,756 shares of Entrada Therapeutics common stock at a weighted average price of $6.93 per share. The following day, July 31, 2026, an additional 1,718 shares were sold at a price of $6.85 per share. The sales came as the stock has surged 24.53% over the past week, according to InvestingPro data, with shares currently trading at $7.26—above the platform’s Fair Value estimate of $6.76, suggesting the stock may be slightly overvalued.

All reported sales were conducted indirectly through 5AM Ventures V, L.P. Following these transactions, 5AM Ventures V, L.P. holds 2,846,592 shares of Entrada Therapeutics common stock. Additionally, 5AM Opportunities I, L.P. holds 1,093,313 shares. Dr. Parmar, a managing member of the general partners for both entities, disclaims beneficial ownership of these shares except to the extent of his pecuniary interest. The company is scheduled to report earnings on August 12, just eight days away.

In other recent news, Entrada Therapeutics Inc. has received clearance from an independent Data Monitoring Committee to escalate the dosage in its ongoing ELEVATE-45-201 study for Duchenne Muscular Dystrophy (DMD). The committee’s recommendation allows the company to proceed with Cohort 2 at a 10 mg/kg dose, following a review of safety and pharmacokinetic data from the initial 5 mg/kg dose in Cohort 1. Additionally, Entrada Therapeutics is set to report topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44. The study is double-blind and placebo-controlled, featuring multiple ascending doses. The company plans to host an investor webcast and conference call to discuss these clinical results. These developments mark significant progress in Entrada’s clinical trials, providing important updates for investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.